Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19

[1]  A. Caicedo,et al.  Cognitive impairment or dementia in post-acute COVID-19 syndrome. Two suspects and a perfect detective: Positron emission tomography (PET) scan , 2022, European Neuropsychopharmacology.

[2]  A. Manyande,et al.  Brain Imaging Changes in Patients Recovered From COVID-19: A Narrative Review , 2022, Frontiers in Neuroscience.

[3]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[4]  C. Weiller,et al.  Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome , 2021, The Journal of Nuclear Medicine.

[5]  OUP accepted manuscript , 2022, Brain.

[6]  J. Teeling,et al.  Systemic Inflammation Accelerates Changes in Microglial and Synaptic Markers in an Experimental Model of Chronic Neurodegeneration , 2022, Frontiers in Neuroscience.

[7]  R. Boellaard,et al.  EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3 , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Anonymous.  Neurology of COVID-19 , 2021 .

[9]  L. Ponto,et al.  18F-FDG-PET Imaging for Post-COVID-19 Brain and Skeletal Muscle Alterations , 2021, Viruses.

[10]  K. Törő,et al.  Neurodegenerative proteinopathies associated with neuroinfections , 2021, Journal of Neural Transmission.

[11]  John O. Prior,et al.  Case Report: Behavioral Unresponsiveness in Acute COVID-19 Patients: The Utility of the Motor Behavior Tool-Revised and 18F-FDG PET/CT , 2021, Frontiers in Neurology.

[12]  V. Calhoun,et al.  Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19 , 2021, Neurobiology of Stress.

[13]  C. Weiller,et al.  Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19 , 2021, Brain : a journal of neurology.

[14]  C. Weiller,et al.  Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients , 2021, The Journal of Nuclear Medicine.

[15]  J. Rungby,et al.  Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables , 2021, European Neuropsychopharmacology.

[16]  T. Piccoli,et al.  COVID-19 and Alzheimer’s Disease , 2021, Brain sciences.

[17]  Q. Ning,et al.  Long-term micro-structure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. , 2021, The Journal of clinical investigation.

[18]  K. Akarid,et al.  The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? , 2021, Microbial Pathogenesis.

[19]  A. Priori,et al.  Long-Lasting Cognitive Abnormalities after COVID-19 , 2021, Brain sciences.

[20]  D. Raoult,et al.  18F-FDG brain PET hypometabolism in patients with long COVID , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  K. Hoang-Xuan,et al.  The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2021, The Journal of experimental medicine.

[23]  C. Jack,et al.  Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias , 2020, The Lancet Neurology.

[24]  J. Deus,et al.  Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment , 2020, Brain, Behavior, & Immunity - Health.

[25]  D. Souza,et al.  PET Imaging as a Tool for Assessing COVID-19 Brain Changes , 2020, Trends in Neurosciences.

[26]  Seyed A Safavynia,et al.  The ‘third wave’: impending cognitive and functional decline in COVID-19 survivors , 2020, British Journal of Anaesthesia.

[27]  D. Hervás,et al.  Short‐term neuropsychiatric outcomes and quality of life in COVID‐19 survivors , 2020, medRxiv.

[28]  M. Lubberink,et al.  Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases , 2020, NeuroImage: Clinical.

[29]  Shaojia Lu,et al.  The landscape of cognitive function in recovered COVID-19 patients , 2020, Journal of Psychiatric Research.

[30]  F. Potus,et al.  Novel insights on the pulmonary vascular consequences of COVID-19 , 2020, American journal of physiology. Lung cellular and molecular physiology.

[31]  S. Farhadian,et al.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. , 2020, JAMA neurology.

[32]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[33]  M. Heneka,et al.  The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease , 2020, Immunology and cell biology.

[34]  A. Larbi,et al.  Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer’s disease? , 2019, Journal of NeuroVirology.

[35]  Seyed A Safavynia,et al.  The Role of Neuroinflammation in Postoperative Cognitive Dysfunction: Moving From Hypothesis to Treatment , 2019, Front. Psychiatry.

[36]  A. Alavi,et al.  Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  F Nobili,et al.  European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus , 2018, European journal of neurology.

[38]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[39]  Koen Van Laere,et al.  SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0 , 2016, The Journal of Nuclear Medicine.

[40]  M. Murphy,et al.  Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[41]  D. Olason,et al.  The Beck Depression Inventory Second Edition (BDI-II): Psychometric properties in Icelandic student and patient populations , 2008, Nordic journal of psychiatry.

[42]  S. Sorbi,et al.  The Rao’s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population , 2006, Multiple sclerosis.

[43]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.